📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
44 announcements match the current filters (relevance ≥ 5).
Senores Pharma FY26: Subsidiary Reports Rs 579 Cr Revenue and Rs 103 Cr PAT
Senores Pharmaceuticals has approved its audited financial results for FY26, showing significant performance from its subsidiary operations. The subsidiary reported a total revenue of Rs 579.05 crores and a net profit after tax of Rs 102.91 crores for the fiscal year. The company also announced the resignation of its Company Secretary, Vinay Kumar Mishra, effective June 10, 2026, and the appointment of Sharp & Tannan Associates as internal auditors. The statutory auditors issued an unmodified opinion on the consolidated financial statements.
Key Highlights
Subsidiary revenue reached Rs 579.05 crores for the financial year ended March 31, 2026
Subsidiary net profit after tax (PAT) reported at Rs 102.91 crores
Total assets of the subsidiary stood at Rs 1,297.26 crores as of year-end
Company Secretary Vinay Kumar Mishra to step down on June 10, 2026
Sharp & Tannan Associates appointed as Internal Auditors for FY 2026-27
👀 What to Watch
Investors should focus on the consolidated growth trajectory as the subsidiary contributes significantly to the bottom line. The clean audit report and strong subsidiary profitability are positive indicators for long-term holding.
Senores Pharma Allots 11.7 Lakh Convertible Warrants to Promoters at ₹812 Each
Senores Pharmaceuticals has approved the allotment of 11.70 lakh convertible warrants to its promoter and promoter group at an exercise price of ₹812 per warrant. The total fundraise is valued at ₹95 crore, with the company already receiving the initial 25% subscription amount of ₹23.75 crore. Upon full conversion within the next 18 months, the promoter group's shareholding is expected to increase from 23.36% to 25.26%. This capital infusion by the promoters signals strong internal confidence in the company's future valuation and growth trajectory.
Key Highlights
Allotment of 11,70,000 convertible warrants at an exercise price of ₹812 per warrant
Total issue size aggregates to ₹95.00 crore, with ₹23.75 crore received as upfront payment
Promoter group shareholding to rise from 23.36% to 25.26% upon full conversion
Warrants are convertible into equity shares in one or more tranches within 18 months
Major allottees include Renosen Pharmaceuticals Private Limited and individual promoters
👀 What to Watch
Investors should take this as a positive sign of promoter commitment and financial backing. The premium pricing of ₹812 per share suggests a floor for the stock's long-term valuation in the eyes of the management.
Senores Pharma Allots 11.7 Lakh Warrants to Promoters at ₹812, Raising ₹95 Crore
Senores Pharmaceuticals has approved the allotment of 11,70,000 convertible warrants to its promoters and promoter group at an exercise price of ₹812 per warrant. The total fundraise is valued at ₹95.00 crore, with the company already receiving 25% of the subscription price amounting to ₹23.75 crore. Upon full conversion within the 18-month window, the promoter group's shareholding is expected to increase from 23.36% to 25.26%. This capital infusion by the promoters signals strong internal confidence in the company's future valuation and growth trajectory.
Key Highlights
Allotment of 11,70,000 convertible warrants at an exercise price of ₹812 per warrant.
Total aggregate fundraise of ₹95.00 crore, with ₹23.75 crore received as the initial 25% subscription.
Promoter and promoter group shareholding to rise from 23.36% to 25.26% post-conversion.
Warrants are convertible into equity shares in one or more tranches within a maximum period of 18 months.
👀 What to Watch
Investors should take this as a positive signal of promoter commitment and long-term confidence in the company. Monitor the company's upcoming quarterly results to see how this capital infusion supports operational expansion.
Senores Pharma Appoints Jatin Gajjar as CTO; R&D President Manohar Lalge Resigns
Senores Pharmaceuticals has announced a leadership transition effective March 17, 2026. Mr. Jatin Gajjar, a veteran with over 30 years of experience in the pharmaceutical sector, has been appointed as the Chief Technology Officer (CTO) and designated as Senior Management Personnel. Concurrently, Mr. Manohar Lalge has resigned from his role as President of Research and Development. The new CTO brings extensive experience from major industry players like Sun Pharma, Zydus Cadila, and Amneal Pharmaceuticals.
Key Highlights
Mr. Jatin Gajjar appointed as Chief Technology Officer and Senior Management Personnel effective March 17, 2026.
Mr. Manohar Lalge resigned as President – Research and Development effective close of business hours on March 17, 2026.
New CTO Jatin Gajjar possesses over 30 years of leadership experience in manufacturing operations and product development.
The appointment was approved by the Board of Directors via circular resolution on March 17, 2026.
👀 What to Watch
Investors should monitor the transition in the R&D department to ensure there is no disruption in the company's product pipeline or regulatory filing timelines. The addition of an experienced CTO from top-tier pharma companies is a positive sign for operational execution.
Senores Pharmaceuticals Appoints Jatin Gajjar as CTO; R&D Head Manohar Lalge Resigns
Senores Pharmaceuticals has announced a leadership transition with the appointment of Mr. Jatin Gajjar as Chief Technology Officer (CTO) and Senior Management Personnel, effective March 17, 2026. Mr. Gajjar brings over 30 years of experience from top-tier firms like Sun Pharma and Zydus Cadila, specializing in complex formulations and injectables. Concurrently, Mr. Manohar Lalge has resigned from his role as President of Research and Development. This change reflects a strategic shift in managing the company's R&D and technological innovation pipeline.
Key Highlights
Mr. Jatin Gajjar appointed as Chief Technology Officer (CTO) effective March 17, 2026.
Mr. Gajjar has over 30 years of experience in pharma technology, manufacturing, and product development.
Outgoing President of R&D, Mr. Manohar Lalge, resigned effective close of business on March 17, 2026.
New CTO has previous leadership experience at global majors including Sun Pharma, Amneal, and Zydus Cadila.
👀 What to Watch
Investors should watch for any shifts in R&D focus or delays in product filings during this leadership transition. The appointment of a veteran with 30+ years of experience is a positive sign for the company's technical execution.
Senores Pharma Clarifies Use of Funds from 11.7 Lakh Warrant Issue for Subsidiary Working Capital
Senores Pharmaceuticals has issued a clarification regarding its proposed preferential issue of 1,170,000 convertible equity warrants. The company specified that a portion of the funds raised will be utilized to provide loans to its 75%-owned subsidiary, Apnar Pharma Private Limited, to meet its working capital requirements. This follows the company's acquisition of the majority stake in Apnar Pharma in December 2025. The disclosure provides transparency on capital allocation following the upcoming Extra-Ordinary General Meeting.
Key Highlights
Proposed issue and allotment of 11,70,000 convertible equity warrants via preferential issue.
Funds earmarked for granting loans to subsidiary Apnar Pharma Private Limited for working capital.
Company confirms 75% ownership of Apnar Pharma following an acquisition in December 2025.
Clarification issued as an amendment to the EGM notice dated January 07, 2026.
👀 What to Watch
Investors should monitor the successful completion of the warrant issue and the subsequent impact of the working capital infusion on Apnar Pharma's operational performance.
Senores Pharma Clarifies Preferential Issue of 11.7 Lakh Warrants at ₹812 Per Share
Senores Pharmaceuticals has issued a clarification regarding its upcoming preferential issue of 11,70,000 convertible equity warrants. The company has fixed the fair value for the conversion of these warrants at ₹812.00 per share, based on a valuation report by Maitri Valuation Private Limited. Although the issue is less than 5% of the post-issue capital, the company provided these details to comply with its Articles of Association. The valuation methodology assigned 100% weightage to the Market Approach as it yielded the highest floor price compared to Asset and Income approaches.
Key Highlights
Proposed issue and allotment of 11,70,000 convertible equity warrants on a preferential basis.
Fair value for conversion of warrants determined at ₹812.00 per share.
Valuation methodology assigned 100% weightage to the Market Price Method.
The quantum of the proposed issue is less than 5% of the post-issue fully diluted share capital.
Independent valuation conducted by Maitri Valuation Private Limited as per company Articles of Association.
👀 What to Watch
Investors should monitor the upcoming Extra-Ordinary General Meeting results for formal approval of this fundraise. The pricing at ₹812 provides a benchmark for the company's internal valuation of its equity.
Senores Pharma Shareholders Approve 11.7 Lakh Convertible Warrants Issue to Promoters
Senores Pharmaceuticals Limited has received shareholder approval for the issuance of 11,70,000 convertible equity warrants to the promoter group on a preferential basis. The special resolution was passed with a significant majority of 96.45% during the EGM held on January 31, 2026. Notably, while the resolution passed, 25.21% of institutional votes were cast against the proposal. This issuance represents a strategic capital infusion by the promoters, signaling long-term commitment to the company's growth.
Key Highlights
Approved issuance of 11,70,000 convertible equity warrants to the Promoter and Promoter Group.
The special resolution was passed with 96.455% votes in favor and 3.545% against.
Public Institutions cast 6,42,044 votes (25.21% of their polled votes) against the resolution.
A total of 1,81,11,053 votes were polled during the EGM process.
👀 What to Watch
The promoter's decision to infuse capital via warrants is a positive signal of confidence; however, investors should monitor the specific pricing and use of proceeds. Keep an eye on the eventual conversion of these warrants into equity and its impact on EPS dilution.
Senores Pharma EGM Approves 11.70 Lakh Convertible Warrants to Promoters
Senores Pharmaceuticals Limited held an Extra-Ordinary General Meeting (EGM) on January 31, 2026, to approve a significant fundraise. The company sought shareholder approval for the issuance of 11,70,000 convertible equity warrants on a preferential basis. These warrants are being issued specifically to the Promoter and Promoter Group category, indicating a capital infusion from the company's leadership. The resolution was presented as a special resolution, and the final voting results are expected to be submitted shortly.
Key Highlights
Issuance of 11,70,000 convertible equity warrants approved via special resolution
Fundraise conducted through a preferential issue on a private placement basis
Warrants exclusively allocated to the Promoter and Promoter Group category
EGM held via Video Conferencing with 48 members in attendance
Remote e-voting was conducted between January 28 and January 30, 2026
👀 What to Watch
Investors should view the promoter-led capital infusion as a sign of confidence in the company's long-term growth. Monitor the official disclosure of the warrant conversion price to evaluate the potential equity dilution.
Senores Pharma Q3FY26 PAT Surges 85% YoY; ANDA Portfolio Quadruples to 46
Senores Pharmaceuticals reported a robust Q3FY26 with consolidated revenue growing 64% YoY to ₹175 crores and PAT increasing 85% to ₹32 crores. The company's ANDA portfolio has expanded significantly from 12 to 46 approved products within a year, providing a strong pipeline for future launches. Management maintained its FY26 guidance of 50% revenue growth and 100% PAT growth, supported by the recent acquisition of Apnar Pharma. The India branded generics business also showed explosive growth, increasing six-fold during the quarter.
Key Highlights
Consolidated EBITDA grew 86% YoY to ₹54 crores with margins expanding 360 bps to 30.9%
ANDA portfolio quadrupled to 46 approved products, with 28 approved ANDAs currently available for launch
Completed 75% acquisition of Apnar Pharma, targeting ₹120-150 crores revenue from this unit in FY27
India branded generics revenue grew 6x YoY to ₹10.5 crores in Q3FY26
9MFY26 PAT more than doubled YoY to ₹84 crores, tracking ahead of annual guidance
👀 What to Watch
Investors should view the strong execution and margin expansion positively, especially the rapid scaling of the ANDA portfolio and the strategic US acquisition. Monitor the integration of Apnar Pharma and the rollout of the 28 approved-but-unlaunched ANDAs as key growth drivers.
Senores Pharmaceuticals Reports Zero Deviation in Utilization of Rs 500 Cr IPO Proceeds
Senores Pharmaceuticals has confirmed that there were no deviations in the utilization of the Rs 500 crore raised via its December 2024 IPO for the quarter ended December 31, 2025. As of the reporting date, the company has successfully deployed Rs 362.12 crore towards its stated objectives. Key expenditures include debt repayment of approximately Rs 93.3 crore and working capital funding of nearly Rs 99 crore. The audit committee and monitoring agency, CARE Ratings, have reviewed and validated these findings.
Key Highlights
Total IPO proceeds of Rs 500 crore raised on December 26, 2024, with zero deviation reported.
Cumulative utilization of funds stands at Rs 362.12 crore as of December 31, 2025.
Rs 107 crore allocated for Havix facility capex, with Rs 6.98 crore utilized to date.
Debt repayment of Rs 73.10 crore for the company and Rs 20.20 crore for subsidiaries has been completed.
Unutilized amounts of Rs 0.40 crore from debt repayment were redirected to General Corporate Purposes (GCP) as per board approval.
👀 What to Watch
Investors should track the deployment of the remaining Rs 100 crore earmarked for the Havix sterile injection facility, as this is a key growth driver. The completion of debt repayment is a positive step for the company's financial health.
Senores Pharma Q3 FY26 PAT Jumps 105% YoY to ₹33.6 Cr; EBITDA Margins Expand to 30.9%
Senores Pharmaceuticals reported a robust Q3 FY26 with total income growing 64.1% YoY to ₹174.6 crore. Net profit (PAT) surged 104.7% YoY to ₹33.6 crore, supported by a significant 360 bps expansion in EBITDA margins to 30.9%. The company successfully completed a 75% stake acquisition in Apnar Pharmaceuticals, adding USFDA-approved facilities and 5 ANDAs to its portfolio. Regulated markets remain the primary growth driver, contributing 65% of total revenue with high EBITDA margins of 40%.
Key Highlights
Total Income for Q3 FY26 grew 64.1% YoY to ₹174.6 crore; 9M FY26 income reached ₹474.3 crore.
EBITDA increased by 85.9% YoY to ₹54.0 crore in Q3, with margins improving from 27.3% to 30.9%.
Completed 75% acquisition of Apnar Pharma for an Enterprise Value of ~₹91 crore to boost US and UK market access.
Strong product pipeline with 46 approved ANDAs (137 strengths) and 22 additional ANDAs currently under development.
Emerging markets revenue grew 48% YoY in Q3, with EBITDA margins jumping from 1% to 13%.
👀 What to Watch
Investors should monitor the integration of Apnar Pharma and the commercialization of the 102 pending ANDA strengths which provide high revenue visibility. The stock remains attractive due to strong margin expansion and a robust cash flow from operations of ₹51 crore for 9M FY26.
Senores Pharma Q3FY26 PAT Surges 105% YoY to Rs 34 Cr; Revenue up 64%
Senores Pharmaceuticals reported a stellar performance for Q3FY26, with consolidated revenue growing 64% YoY to Rs 175 crore and PAT doubling to Rs 34 crore. The company's regulated markets business remains the primary driver, contributing 64.5% of revenue with a strong 40% EBITDA margin. Significant improvement was seen in the emerging markets segment, where EBITDA margins jumped from 1% to 13% YoY. The integration of Apnar Pharmaceuticals is progressing ahead of schedule, with 75% of the stake already acquired and the remainder expected by Q2FY27.
Key Highlights
Consolidated Q3FY26 Revenue grew 64% YoY to Rs 175 crore, while PAT rose 105% to Rs 34 crore.
Regulated market revenue increased 60.5% YoY to Rs 112.7 crore with a robust 40% EBITDA margin.
Emerging markets business saw a massive margin expansion of 1,200 bps, reaching 13% EBITDA margin in Q3.
Strong product pipeline with 46 approved ANDAs and 22 additional ANDAs currently under development.
Operating Cash Flow for 9MFY26 stood at Rs 51 crore, showing significantly improved EBITDA-to-OCF conversion.
👀 What to Watch
Investors should view these results positively given the high growth in both top-line and bottom-line along with significant margin expansion in emerging markets. Monitor the successful launch of the 28 approved-but-unlaunched ANDAs as a key growth catalyst for FY27.
Senores Pharma Q3 FY26 PAT Surges 105% to Rs 34 Cr; Revenue Up 64% YoY
Senores Pharmaceuticals reported a robust Q3 FY26 with a 64% YoY increase in total income to Rs 175 crore and a 105% surge in PAT to Rs 34 crore. The company's regulated markets segment grew 60.5% YoY with a strong 40% EBITDA margin, while emerging markets saw a significant margin expansion from 1% to 13%. The acquisition of Apnar Pharmaceuticals is progressing well, with 75% stake already acquired and integration happening faster than expected. With 46 approved ANDAs and over 100 strengths yet to be launched, the company maintains a strong growth pipeline.
Key Highlights
Q3 FY26 PAT grew 105% YoY to Rs 34 crore, while 9M FY26 PAT rose 110% to Rs 85 crore.
Consolidated EBITDA for Q3 FY26 stood at Rs 54 crore, representing an 86% YoY growth.
Regulated market revenue grew 60.5% YoY to Rs 112.7 crore with a high EBITDA margin of 40%.
Emerging markets EBITDA margin jumped 1,200 bps YoY to 13% in Q3 FY26.
Strong product pipeline with 46 approved ANDAs and 22 more under development.
👀 What to Watch
The stock shows strong operational leverage and margin expansion across geographies. Investors should monitor the launch of the 100+ pending ANDA strengths as a key growth catalyst.
Senores Pharmaceuticals Q3 PAT Surges 104% YoY to ₹33.58 Cr; Revenue Up 69%
Senores Pharmaceuticals reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 69.4% YoY to ₹174.56 crore. Net profit for the quarter more than doubled, reaching ₹33.58 crore compared to ₹16.42 crore in the same period last year. The company has successfully utilized ₹362.12 crore of its ₹500 crore IPO proceeds, primarily for debt repayment and working capital. For the nine-month period ended December 2025, the company has already surpassed its total FY25 profit, indicating strong growth momentum.
Key Highlights
Consolidated Revenue from operations increased by 69.4% YoY to ₹174.56 crore in Q3 FY26.
Net Profit after tax (PAT) surged 104.5% YoY to ₹33.58 crore from ₹16.42 crore.
Nine-month (9M FY26) PAT stands at ₹84.86 crore, significantly exceeding the full-year FY25 PAT of ₹58.34 crore.
Company utilized ₹362.12 crore of IPO proceeds, with ₹137.88 crore remaining for future expansion and sterile injection facility setup.
Basic EPS for the quarter improved to ₹7.29 from ₹5.04 in the previous year's corresponding quarter.
👀 What to Watch
The company is showing exceptional growth post-listing, with 9M profits already far exceeding previous annual figures. Investors should maintain a positive outlook while monitoring the progress of the new sterile injection facility in Atlanta, which is a key growth driver.
Senores Pharmaceuticals acquires 75% stake in Apnar Pharma for ₹11.46 Crore
Senores Pharmaceuticals has successfully completed the acquisition of a 75% majority stake in Apnar Pharma Private Limited. The company acquired 56,63,804 equity shares for a total cash consideration of ₹11.46 crore on January 16, 2026. This transaction is part of a phased acquisition strategy to eventually own 100% of the target company. The acquisition of the remaining 25% equity interest is scheduled to be completed by the second quarter of FY 2027.
Key Highlights
Acquired 56,63,804 equity shares of Apnar Pharma Private Limited
Total consideration paid for the current tranche is ₹11,45,78,755
Company now holds a 75% controlling interest in the target entity
Balance 25% stake acquisition is on track for completion by Q2 FY 2027
👀 What to Watch
Investors should view this as a positive step towards inorganic growth and monitor the impact of this consolidation on the company's upcoming quarterly earnings. Watch for the final 25% stake acquisition in FY 2027 to complete the full integration.
Senores Pharma to Raise ₹95 Crore via Preferential Issue of 11.7 Lakh Warrants to Promoters
Senores Pharmaceuticals has called an Extraordinary General Meeting (EGM) on January 31, 2026, to seek approval for a preferential issue of 11,70,000 convertible equity warrants. The warrants are priced at ₹812 each, aiming to raise approximately ₹95 crore exclusively from the promoter and promoter group. Allottees will pay 25% of the total consideration upfront, with the remaining 75% payable upon conversion into equity shares within 18 months. This capital infusion signifies strong promoter commitment and provides the company with significant growth capital.
Key Highlights
Issuance of 11,70,000 convertible equity warrants at a fixed price of ₹812 per warrant.
Total fundraise of ₹95,00,40,000 from five entities within the promoter and promoter group.
Warrants are convertible into equity shares of ₹10 face value within a maximum period of 18 months.
Mandatory upfront payment of 25% (₹203 per warrant) with the balance 75% due at conversion.
Relevant date for price determination set as January 01, 2026, as per SEBI ICDR Regulations.
👀 What to Watch
Investors should view this as a positive signal of promoter confidence and long-term commitment to the company. Monitor the EGM outcome and subsequent announcements regarding the specific utilization of these funds for business expansion.
Senores Pharma to Raise ₹95 Crore via Preferential Issue of Warrants to Promoters at ₹812/Share
Senores Pharmaceuticals has approved a preferential issue of 11.70 lakh convertible equity warrants to its promoter group at a price of ₹812 per warrant. The total fundraise amounts to approximately ₹95.00 crore, intended to strengthen the company's capital position. Promoters will contribute 25% of the amount upfront, with the balance payable upon conversion within 18 months. This issuance will increase the promoter group's stake from 23.36% to 25.26% on a fully diluted basis.
Key Highlights
Issuance of 11,70,000 fully convertible warrants at ₹812 each, including a premium of ₹802.
Total capital infusion of ₹95,00,40,000 from five promoter and promoter group entities.
Promoter holding to increase by 1.9% to reach 25.26% on a fully diluted basis.
Warrants carry an 18-month conversion period with 25% upfront payment required at allotment.
Extra-ordinary General Meeting (EGM) for shareholder approval is scheduled for January 31, 2026.
👀 What to Watch
The promoter group's decision to infuse capital at ₹812 per share signals strong internal confidence in the company's valuation and future prospects. Investors should monitor the upcoming EGM and subsequent deployment of these funds for growth initiatives.
Senores Pharma acquires Apnar Pharma for ₹91 Cr; targets ₹250 Cr peak revenue by FY28
Senores Pharmaceuticals is acquiring Apnar Pharma for an enterprise value of ₹91 crores, including a USFDA-approved facility in Gujarat and five high-value ANDA assets. The transaction involves assuming ₹76 crores of debt and paying ₹15 crores in equity, funded through IPO proceeds and internal accruals. Management targets ₹100 crore revenue in FY27, with peak potential reaching ₹250 crore by FY28. This strategic move aims to optimize costs by shifting production from the US to India and tapping into a $700 million market opportunity.
Key Highlights
Enterprise value of ₹91 crores with ₹76 crores debt assumption and ₹15 crores equity payment.
Acquisition includes 5 ANDA assets with a total market opportunity of over $700 million.
Gujarat facility has USFDA, UK MHRA, and Health Canada approvals with 275 million capsule capacity.
Management expects ₹100 crore revenue in FY27 and peak revenue of ₹250 crore by FY28.
Commercialization of two validated products is expected to begin as early as January 2026.
👀 What to Watch
Investors should monitor the successful transfer of production to the India facility and the resulting impact on operating margins. The acquisition provides a high-value entry into additional regulated markets like the UK and Canada at a distressed valuation.
Senores Pharmaceuticals Grants ₹15 Crore Inter-Corporate Loan to Apnar Pharma
Senores Pharmaceuticals has entered into a loan agreement to provide up to ₹15 crore to Apnar Pharma Private Limited. This financial support follows a Share Purchase Agreement (SPA) signed on December 15, 2025, signaling a strategic acquisition or partnership move. The loan carries a 10% annual interest rate and is repayable on demand, with funds specifically earmarked to help Apnar discharge liabilities as per the SPA. Currently, ₹1 crore remains outstanding from a previous smaller loan arrangement between the two entities.
Key Highlights
Inter-corporate loan of up to ₹15 crore granted to Apnar Pharma Private Limited.
Interest rate set at 10% per annum on an arm's length basis.
Loan is unsecured and repayable on demand by Senores Pharmaceuticals.
Funds intended for Apnar to discharge liabilities specified in the SPA dated December 15, 2025.
Existing outstanding loan balance of ₹1 crore already exists from a prior ₹1.5 crore facility.
👀 What to Watch
Investors should monitor the upcoming acquisition of Apnar Pharma as this loan is a strategic step toward closing the deal. Assess the impact of this capital allocation on Senores' balance sheet and the potential synergies from the target company.
